Confido Health

Cover Block

Open sources

Field	Value
Name	Confido Health
Tagline	AI-powered voice agents and workflow automation for healthcare providers to manage patient interactions.
Headquarters	New York, US [Crunchbase]
Founded	2022 [Crunchbase]
Stage	Series A [The Economic Times, October 2025]
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2): Chetan Reddy, Vichar Shroff [Forbes, December 2024]
Funding Label	Series A
Total Disclosed	~$25,500,000, comprising a $3,000,000 Seed, a $10,000,000 Series A, and a $12,500,000 Series A extension [Forbes, December 2024] [The Economic Times, October 2025] [PR Newswire, October 2026]

Links

Open sources

• Website: https://www.confido.health/
• LinkedIn: https://www.linkedin.com/company/confido-health

What an Investor Needs First

PUBLIC Confido Health builds AI-powered voice agents and workflow automation for healthcare providers, a category drawing investor attention because the company has moved from scheduling-focused call automation to a broader administrative operations layer while also reporting rapid deployment growth through 2026 [Forbes, December 2024] [The Economic Times, October 2025] [The Economic Times, October 2026]. Founded in 2022 in New York by Chetan Reddy and Vichar Shroff, the company entered through a plain but consequential wedge: patient phone calls and scheduling, which Forbes reported account for roughly 30% to 40% of provider inquiries, before expanding into referrals, prescription refills, payments, insurance verification, and intake workflows [Forbes, September 2025] [The Economic Times, October 2025].

The product case rests less on model novelty than on workflow placement. Confido says its agents answer and authenticate patient calls, schedule appointments, manage administrative requests, and operate inside existing healthcare systems, and third-party coverage points to measurable results at Dallas Renal Group, where inbound wait times reportedly fell to about 15 seconds and more than 66% of patients confirmed appointments instantly on outbound calls [Forbes, September 2025] [hitconsultant.net, September 2025] [PR Newswire, October 2026].

The founding bench is still publicly thin, but the relevant facts are directionally useful. Reddy is identified as co-founder and CEO, Shroff as co-founder, and public profiles tie Reddy to a prior data science role at HCL Technologies, which supports technical credibility even if the public record does not yet offer a deep operating history in scaled healthcare software [Forbes, December 2024] [LinkedIn, retrieved 2026] [LinkedIn, retrieved 2026].

On capitalization, the company has disclosed $25.5 million across a $3 million seed round in December 2024, a $10 million Series A in September 2025, and a $12.5 million Series A extension in October 2026, with backing from Together Fund, Blume Ventures, Z47, and others; the business model is described as SaaS serving healthcare providers and multi-location practices [Forbes, December 2024] [The Economic Times, October 2025] [PR Newswire, October 2026]. Reported traction has also scaled materially, from roughly 20 healthcare providers representing about 50,000 patients in late 2024 to 3,200 healthcare providers across more than 1,500 sites in 27 U.S. states by October 2026, though investors should treat the later figures as management-reported until more independent customer-level corroboration surfaces [Forbes, December 2024] [The Economic Times, October 2026].

Over the next 12 to 18 months, the key question is whether Confido can convert early proof points in voice automation into durable, multi-workflow penetration across provider operations without service quality slipping as scope expands. The company looks interesting because it is selling into a visible administrative pain point, but the next leg of investor confidence will depend on independently validated retention, breadth of deployment beyond scheduling, and evidence that the broader CareOS platform carries the same operational gains as the initial call-handling wedge [Yahoo Finance, September 2025] [The Economic Times, October 2026] [Confido Health, retrieved 2026].

Partially corroborated -- Relies on named public sources including Forbes, The Economic Times, LinkedIn, PR Newswire, and company materials, but several operating metrics and product-scope claims remain management-reported or only partially corroborated.

Taxonomy Snapshot

Axis	Value
Stage	Series A
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	$25,500,000 disclosed

Inside the Company

PUBLIC

Confido Health appears to be a New York-based healthtech company focused on administrative automation for healthcare providers, with public materials describing a product centered on AI-powered voice agents and workflow software for patient interactions [Crunchbase] [Confido Health]. The basic company record is reasonably clear on the public web: Crunchbase lists the company as founded in 2022 and headquartered in New York, while the company website presents the business as an agentic AI platform for healthcare operations [Crunchbase] [Confido Health].

The public chronology is still short, but the milestones that can be tied directly to company-controlled or directory-style records are straightforward. Confido Health was founded in 2022, and its website now positions the product beyond phone automation into front-, mid-, and back-office workflows, including scheduling, insurance checks, referrals, and patient balances [Crunchbase] [Confido Health]. The same site also frames the product around 24/7 inbound and outbound patient communication and workflow execution inside provider systems, which suggests the company is trying to become a broader operating layer rather than a single-point scheduling tool [Confido Health].

Partially corroborated -- This section relies on Crunchbase and the company website, but several product and positioning claims are company-controlled and not independently corroborated here.

Under the Hood

MIXED

The product story is fairly clear even with limited technical disclosure: Confido Health is selling AI voice agents for healthcare operations, with phone calls and scheduling as the initial wedge, then expanding into adjacent administrative workflows that sit close to the patient access function [Forbes, December 2024] [Forbes, September 2025] [The Economic Times, October 2025]. Public descriptions consistently say the system answers and authenticates patient calls, books appointments, manages referrals and prescription refill requests, handles payment-related questions, and returns status updates, all aimed at provider groups rather than consumers [The Economic Times, October 2025] [Yahoo Finance, September 2025]. By 2026, the company had begun describing CareOS as an agentic AI operations platform extending beyond voice into broader administrative work, which is directionally important because it suggests a move from a point solution toward workflow orchestration inside clinic operations [PR Newswire, October 2026] [Health Technology Net, October 2026].

The evidence on workflow depth is mixed. Company materials say the platform works across front, mid, and back office functions, including insurance checks, patient balances, after-hours coverage, and coordination across existing healthcare systems, and individual employee LinkedIn pages describe the voice assistant as operating directly within a clinic's system of record [Confido Health, retrieved 2026] [LinkedIn, retrieved 2026]. Those claims fit the broader market narrative around healthcare administrative automation, but most of the implementation detail remains company-described rather than independently demonstrated in technical documentation or a verified public demo [Confido Health, retrieved 2026]. The clearest externally reported proof point is operational rather than architectural: Dallas Renal Group said inbound wait times fell to about 15 seconds and more than 66% of patients confirmed appointments instantly on outbound calls, which supports the usefulness of the voice workflow even if it does not fully validate the breadth of the underlying platform claims [hitconsultant.net, September 2025] [Forbes, September 2025].

What is not yet public is just as relevant. There is no verified public detail here on model providers, deployment architecture, compliance tooling, error handling, escalation logic, or integration method beyond general claims that the software works within existing systems and can document interactions in one call [Confido Health, retrieved 2026] [Yahoo Finance, September 2025]. That leaves the technology assessment centered on product surface and observed outcomes rather than deep stack defensibility. On the evidence available, Confido appears best understood as a healthcare operations automation layer built around voice as the acquisition channel, with announced expansion into adjacent admin workflows, rather than as a clinical AI product or a telehealth service [Forbes, September 2025] [PR Newswire, October 2026] [Confido Health, retrieved 2026].

Partially corroborated -- Core product positioning is corroborated by multiple public sources, but several capability and workflow-depth claims in this section rely on company materials or employee LinkedIn descriptions rather than independent technical verification.

Market Research

Open sources

Healthcare administration is a large enough cost center, and patient access is painful enough, that even narrowly scoped automation can matter if it works inside existing provider workflows [Yahoo Finance, September 2025] [Forbes, September 2025]. Confido is selling into that pressure point rather than trying to change clinical care itself: the public record describes a product aimed at phone calls, scheduling, referrals, refills, payments, insurance verification, intake, and related administrative tasks for providers [Forbes, December 2024] [The Economic Times, October 2025]. The useful framing here is not a precise TAM, because no named third-party market sizing report was provided in the source set, but an adjacent operational budget line. In the cited reporting, scheduling alone represented roughly 30% to 40% of provider inquiries, which suggests a sizable initial wedge even before broader workflow expansion [Forbes, September 2025].

A hard market-size figure would be overstated from the available evidence, so the cleaner read is that Confido sits at the intersection of several established spend categories: contact-center software for healthcare, patient-access operations, revenue-cycle workflow, and horizontal AI automation for service businesses [Forbes, December 2024] [The Economic Times, October 2025]. Public materials also position the company beyond call answering, into a wider administrative operating layer that connects providers, insurers, and pharmacies across existing systems, though those broader capability claims are partly company-described and should be treated with more caution than the funding and customer-deployment reporting [PR Newswire, October 2026] [Confido Health, retrieved 2026].

Market angle	Public evidence	Relevance to Confido
Patient access and phone operations	Scheduling represented roughly 30% to 40% of provider inquiries [Forbes, September 2025]	Supports a high-frequency, workflow-first entry point for voice automation
Patient communication resolution gap	Less than half of patient calls get resolved on the first attempt in the healthcare market [Yahoo Finance, September 2025]	Suggests providers have a service and labor problem, not only a software procurement problem
Multi-site provider operations	Confido was reported at more than 20 customers across over 75 U.S. locations in 2025, then 3,200 providers across more than 1,500 sites in 27 states in 2026 [The Economic Times, December 2024] [The Economic Times, October 2026]	Indicates the target market includes scaled provider groups where standardized workflows can justify automation spend

The table does not produce a formal TAM, but it does show why this category is attracting capital. The common thread is volume: repetitive patient interactions, uneven first-call resolution, and distributed provider footprints all favor software that can absorb routine demand if it integrates into real operating processes.

Demand drivers in the cited research are concrete and mostly operational. Providers appear to be buying against missed calls, long wait times, and labor-intensive scheduling, not against a speculative AI thesis [Forbes, September 2025] [Yahoo Finance, September 2025]. The Dallas Renal Group example is only one customer case, but it is directionally useful: reported wait times fell to about 15 seconds, and more than two-thirds of outbound appointment confirmations were immediate, which is the kind of measurable throughput improvement that can justify software adoption in access-heavy specialties [hitconsultant.net, September 2025] [Forbes, September 2025]. Just as important, Confido's product surface expands from front-desk voice work into adjacent administrative jobs like referrals, refills, payments, intake, and insurance checks, which broadens the budget owner from reception to operations and revenue-cycle teams over time [The Economic Times, October 2025] [PR Newswire, October 2026].

The adjacent and substitute markets are straightforward. A provider could address the same pain with larger call-center teams, outsourced answering services, EHR-native workflow tooling, generic contact-center platforms, or horizontal AI voice software adapted to healthcare [Confido Health, retrieved 2026] [PR Newswire, October 2026]. That matters because the market is not being created from zero; it is being contested across labor, legacy software, and new AI infrastructure. Confido's public positioning suggests its bet is that healthcare buyers prefer a domain-specific layer that can work inside the system of record and handle administrative communication end to end, rather than a stand-alone bot or a general-purpose telephony product [Connor O'Grady - Confido Health | LinkedIn, retrieved 2026] [Health Technology Net, October 2026].

Regulatory and macro forces cut both ways, but the broad direction is supportive for administrative automation. On the supportive side, the company is focused on non-diagnostic, non-treatment workflows, which keeps the initial use case closer to operations than to regulated clinical decision-making [Confido Health, retrieved 2026]. On the constraining side, healthcare remains integration-heavy and trust-sensitive, so product expansion depends on working reliably within clinic systems, preserving documentation quality, and handling patient communications in a compliant manner, all while persuading provider groups that automation will improve access rather than create new failure points [Confido Health, retrieved 2026] [PR Newswire, October 2026]. The public evidence supports a live and growing market need. It is less definitive on the ultimate market ceiling, which is still better treated as a diligence question than as a modeled certainty.

Partially corroborated -- This section relies on named public reporting from Forbes, The Economic Times, Yahoo Finance, PR Newswire, Hit Consultant, LinkedIn, and the company website, but it does not include an independently cited third-party TAM study and several broader market statements rest on company-described product positioning.

Competition and Substitutes

MIXED Confido Health is positioned less as a standalone call-answering tool and more as an operating layer for provider-side administrative work, but the public record here is thinner on named direct rivals than on the company’s own product expansion claims [Forbes, September 2025] [The Economic Times, October 2025] [PR Newswire, October 2026].

The clearest public segmentation is by substitute, not by a fully enumerated peer set. At the incumbent end, Confido is competing against in-house front-desk teams, call centers, and the scheduling and patient-access workflows embedded inside existing provider systems, because its initial wedge is patient phone calls and appointment management [Forbes, December 2024] [Forbes, September 2025]. Adjacent substitutes include healthcare IT platforms that already sit in the workflow, particularly the operating teams around Innovaccer and Memora Health, which appeared in Confido’s 2025 financing as participating healthcare operators rather than as disclosed commercial partners [The Economic Times, October 2025]. That distinction matters. It suggests Confido is selling into an ecosystem where workflow ownership is contested by software vendors, service providers, and providers’ own staff, even if the available sources stop short of mapping direct account-by-account competition.

The company’s edge today appears to rest on wedge selection and proof points, not on a publicly demonstrated distribution lock. Confido chose a high-frequency problem, phone-based patient access, where scheduling alone represented roughly 30% to 40% of provider inquiries according to Forbes, and it has at least one named customer reference in Dallas Renal Group with reported improvement in wait times and outbound confirmations [Forbes, September 2025] [hitconsultant.net, September 2025]. Scale claims also show meaningful movement, from about 20 providers and 50,000 patients in late 2024 to 3,200 healthcare providers across more than 1,500 sites in 27 states by October 2026 [Forbes, December 2024] [The Economic Times, October 2026]. That is commercially relevant if the deployments are sticky, because healthcare administrative workflows tend to become harder to displace once they are connected to scheduling, referrals, refills, and payments across existing systems [The Economic Times, October 2025] [PR Newswire, October 2026]. It is still a perishable advantage. The public evidence does not yet show exclusive data access, a proprietary channel, or a regulatory moat that would prevent larger healthcare software vendors from building similar automation.

The exposure is easiest to see around platform adjacency. Innovaccer and Memora Health are the only named companies in the sourced material besides investors, and both matter because they sit close to provider workflow and patient engagement, where an automation layer can either become embedded or be subsumed by a broader platform [The Economic Times, October 2025]. If one of those broader healthcare software players, or another incumbent with system-of-record access, offers native scheduling, outreach, and administrative orchestration inside the same procurement motion, Confido could be forced to win on implementation speed and specialty workflow depth rather than on platform control. The public record also does not establish that Confido owns a privileged distribution channel through payers, EHR vendors, or large health systems, which leaves it exposed if procurement shifts from point solutions toward bundled workflow suites.

The most plausible 18-month scenario is a market split between specialists that land quickly on voice-driven administrative pain points and broader healthcare platforms that absorb those features over time. In that setup, Confido is a likely winner if provider groups continue buying best-of-breed automation for patient access and back-office throughput, especially in specialties where phone volume and scheduling friction are acute [Forbes, September 2025] [PR Newswire, October 2026]. A likely loser if that bundling dynamic accelerates is any independent voice-first vendor that cannot extend beyond calls into full workflow execution inside the clinic system of record, because the product would risk becoming a feature rather than a control point [Connor O'Grady - Confido Health | LinkedIn, retrieved 2026] [PR Newswire, October 2026]. Confido’s own public messaging indicates it understands that risk and is trying to move from voice automation toward a broader CareOS operations layer, but that strategic move remains earlier in evidence than in proof [Health Technology Net, October 2026] [Confido Health, retrieved 2026].

Opportunity

PUBLIC

The prize here is not a better phone tree, it is the chance to become a system-of-action layer for routine healthcare administration across thousands of provider sites if Confido can turn an initial scheduling wedge into durable workflow ownership [Forbes, September 2025] [PR Newswire, October 2026].

The headline opportunity is straightforward. U.S. providers still field a large volume of patient communication that is repetitive, time-sensitive, and operationally expensive, and Confido appears to have chosen a sensible entry point by starting with calls and scheduling, which Forbes reported represent roughly 30% to 40% of provider inquiries [Forbes, September 2025]. The reason this upside looks reachable rather than purely aspirational is that the company has moved from early traction, about 20 healthcare providers and roughly 50,000 patients by December 2024, to reported deployment across 3,200 healthcare providers, more than 1,500 sites, and 27 states by October 2026, while broadening the product narrative from voice automation into CareOS, an agentic operations platform [Forbes, December 2024] [The Economic Times, October 2026] [PR Newswire, October 2026]. If those reported deployments reflect real workflow penetration rather than light pilots, the plausible long-term outcome is a default operating layer for non-clinical patient access and admin work inside multi-site medical groups.

The upside paths are not identical, and the next leg of value creation depends on which motion proves repeatable at scale.

Scenario	What happens	Catalyst	Why it's plausible
Scheduling wedge becomes platform control	Confido starts with inbound and outbound scheduling, then expands into referrals, refills, payments, insurance verification, and intake until it owns a broad share of front- and mid-office workflows	The expansion of CareOS beyond voice calls into broader administrative workflows gives the company a product path to move from single-use automation to cross-functional workflow ownership [PR Newswire, October 2026]	The company already describes agents handling scheduling first and then expanding into referrals, refills, payments, and insurance-related tasks, which is a credible adjacency map rather than a category jump [Forbes, September 2025] [The Economic Times, October 2025]
Multi-site medical groups standardize on one layer	Private-equity-backed and multi-location provider groups adopt Confido across clinics, creating a repeatable enterprise rollout model	Reported scale from more than 75 U.S. locations in 2025 to more than 1,500 sites in 2026 suggests the product can travel across distributed operations if retention holds [The Economic Times, December 2024] [The Economic Times, October 2026]	The customer evidence points to a buyer set with recurring administrative pain, and Dallas Renal Group's reported reduction in wait times offers a concrete operational proof point for larger group rollouts [hitconsultant.net, September 2025]
Voice agent becomes the patient access gateway	Confido becomes the always-on entry point for patient communication, routing each interaction into the right workflow and system of record	Product claims around answering, authenticating, scheduling, and documenting within existing clinic systems suggest a credible path to becoming the first layer patients interact with [Yahoo Finance, September 2025] [Connor O'Grady - Confido Health	LinkedIn]

The compounding logic is easier to see once the first workflow is in place. If Confido answers calls, authenticates patients, books or changes appointments, and documents the interaction within the clinic's existing system, it gathers process knowledge about how each site handles common administrative events, which should lower deployment friction for adjacent workflows such as referrals, balances, refills, and insurance checks [The Economic Times, October 2025] [Connor O'Grady - Confido Health | LinkedIn] [PR Newswire, October 2026]. In practical terms, one solved use case can become a distribution channel for the next one.

There is also an early operating flywheel in the reported outcomes. Dallas Renal Group said inbound wait times fell to about 15 seconds and that more than 66% of patients confirmed appointments instantly on outbound calls, which suggests automation can improve both service levels and task completion at once [hitconsultant.net, September 2025]. If those results generalize, better responsiveness should make administrators more willing to route additional workflows through the platform, and broader workflow coverage should make the product harder to remove because it is embedded in daily operations rather than used as a narrow answering layer [Forbes, September 2025] [PR Newswire, October 2026].

The size of the win is substantial even without a public market comparable in the supplied sources. Confido has disclosed $25.5 million of funding across seed, Series A, and a Series A extension, with the latest financing earmarked to expand CareOS beyond voice into broader administrative workflows, which frames investor ambition around platform scope rather than a single feature category [Forbes, December 2024] [The Economic Times, October 2025] [PR Newswire, October 2026]. On that evidence alone, a credible upside case is a multibillion-dollar software asset if the company becomes the operating layer across large multi-site provider networks, but that should be read as a scenario, not a forecast, because the public record here does not include revenue, retention, or margin data sufficient to anchor a tighter valuation range [The Economic Times, October 2026] [PR Newswire, October 2026].

Partially corroborated -- This section relies on named-publication reporting from Forbes, The Economic Times, hitconsultant.net, Yahoo Finance, and PR Newswire, but several material product-scope and scale claims remain single-source or company-linked rather than independently corroborated.

Sources

Open sources

1. [Crunchbase] Confido Health | Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/confido-health

2. [The Economic Times, October 2025] Confido Health bags $10 mn led by Blume Ventures | https://b2b.economictimes.indiatimes.com/news/entrepreneur/confido-health-raises-10-million-in-series-a-funding-led-by-blume-ventures/124250688

3. [Forbes, December 2024] How Confido Puts AI Agents To Work To Keep Patients Happy | https://www.forbes.com/sites/davidprosser/2024/12/19/how-confido-puts-ai-agents-to-work-to-keep-patients-happy/

4. [Forbes, September 2025] Inside The Race To Improve The Patient Experience With AI Agents | https://www.forbes.com/sites/davidprosser/2025/09/30/inside-the-race-to-improve-the-patient-experience-with-ai-agents/

5. [PR Newswire, October 2026] Confido Health Expands Agentic Operating Platform to Move Healthcare from Systems of Record to Systems of Action | https://www.prnewswire.com/news-releases/confido-health-expands-agentic-operating-platform-to-move-healthcare-from-systems-of-record-to-systems-of-action-302908090.html

6. [hitconsultant.net, September 2025] Confido Health Raises $10M to Expand AI Voice Agents for Healthcare Practices | https://hitconsultant.net/2025/09/30/confido-health-raises-10m-to-expand-ai-voice-agents-for-healthcare-practices/

7. [LinkedIn, retrieved 2026] Chetan Reddy | LinkedIn | https://www.linkedin.com/

8. [Confido Health, retrieved 2026] Confido Health | Agentic AI for Healthcare Operations | https://www.confido.health/

9. [Yahoo Finance, September 2025] Confido Health Raises $10M to Expand AI Voice Agents for Healthcare Practices | https://finance.yahoo.com/news/confido-health-raises-10m-expand-130000000.html

10. [The Economic Times, October 2026] Healthtech startup Confido Health raises $12.5 million in funding led by Z47 | https://economictimes.indiatimes.com/tech/startups/healthtech-startup-confido-health-raises-12-5-million-in-funding-led-by-z47/articleshow/134947006.cms?from=mdr

11. [The Economic Times, December 2024] Healthtech startup Confido Health raises $3 million in round led by Together Fund | https://economictimes.indiatimes.com/tech/funding/healthtech-startup-confido-health-raises-3-million-in-round-led-by-together-fund/articleshow/116475230.cms

12. [Connor O'Grady - Confido Health | LinkedIn, retrieved 2026] Connor O'Grady - Confido Health | LinkedIn | https://www.linkedin.com/in/connor-o-grady-375788118/

13. [Health Technology Net, October 2026] Confido Health Expands Agentic Operating Platform to Move Healthcare from Systems of Record to Systems of Action | https://www.healthtechnologynet.com/doc/confido-health-expands-agentic-operating-platform-to-move-healthcare-from-systems-of-record-to-systems-of-action-0001